Literature DB >> 7567974

Genetic dissection of Alzheimer disease, a heterogeneous disorder.

G D Schellenberg1.   

Abstract

The genetics of Alzheimer disease (AD) are complex and not completely understood. Mutations in the amyloid precursor protein gene (APP) can cause early-onset autosomal dominant AD. In vitro studies indicate that cells expressing mutant APPs overproduce pathogenic forms of the A beta peptide, the major component of AD amyloid. However, mutations in the APP gene are responsible for 5% or less of all early-onset familial AD. A locus on chromosome 14 is responsible for AD in other early-onset AD families and represents the most severe form of the disease in terms of age of onset and rate of decline. Attempts to identify the AD3 gene by positional cloning methods are underway. At least one additional early-onset AD locus remains to be located. In late-onset AD, the apolipoprotein E gene allele epsilon 4 is a risk factor for AD. This allele appears to act as a dose-dependent age-of-onset modifier. The epsilon 2 allele of this gene may be protective. Other late-onset susceptibility factors remain to be identified.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567974      PMCID: PMC41005          DOI: 10.1073/pnas.92.19.8552

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  137 in total

Review 1.  Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?

Authors:  J T Jarrett; P T Lansbury
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

2.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

Authors:  E H Corder; A M Saunders; W J Strittmatter; D E Schmechel; P C Gaskell; G W Small; A D Roses; J L Haines; M A Pericak-Vance
Journal:  Science       Date:  1993-08-13       Impact factor: 47.728

3.  No linkage to chromosome 14 in Swedish Alzheimer's disease families.

Authors:  L Lannfelt; L Lilius; H Appelgren; K Axelman; C Forsell; L Liu; K Johansson; C Graff
Journal:  Nat Genet       Date:  1993-07       Impact factor: 38.330

4.  Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases.

Authors:  A M Saunders; K Schmader; J C Breitner; M D Benson; W T Brown; L Goldfarb; D Goldgaber; M G Manwaring; M H Szymanski; N McCown
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

5.  Apolipoprotein E polymorphism and Alzheimer's disease.

Authors:  J Poirier; J Davignon; D Bouthillier; S Kogan; P Bertrand; S Gauthier
Journal:  Lancet       Date:  1993-09-18       Impact factor: 79.321

6.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

Authors:  W J Strittmatter; K H Weisgraber; D Y Huang; L M Dong; G S Salvesen; M Pericak-Vance; D Schmechel; A M Saunders; D Goldgaber; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

7.  Screening for the APP codon 670/671 mutations in Alzheimer's disease.

Authors:  H Houlden; F Crawford; M Rossor; M Mullan
Journal:  Neurosci Lett       Date:  1993-05-14       Impact factor: 3.046

8.  Chromosome 14 and late-onset familial Alzheimer disease (FAD).

Authors:  G D Schellenberg; H Payami; E M Wijsman; H T Orr; K A Goddard; L Anderson; E Nemens; J A White; M E Alonso; M J Ball
Journal:  Am J Hum Genet       Date:  1993-09       Impact factor: 11.025

9.  Linkage of familial Alzheimer disease to chromosome 14 in two large early-onset pedigrees: effects of marker allele frequencies on lod scores.

Authors:  A Nechiporuk; P Fain; E Kort; L E Nee; E Frommelt; R J Polinsky; J R Korenberg; S M Pulst
Journal:  Am J Med Genet       Date:  1993-05-01

10.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

View more
  33 in total

Review 1.  Presenilins: structural aspects and posttranslational events.

Authors:  F Checler
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

2.  The ins and outs of presenilin 1 membrane topology.

Authors:  Jinoh Kim; Randy Schekman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

3.  HOP-1, a Caenorhabditis elegans presenilin, appears to be functionally redundant with SEL-12 presenilin and to facilitate LIN-12 and GLP-1 signaling.

Authors:  X Li; I Greenwald
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 4.  Genetics of Alzheimer disease.

Authors:  Lynn M Bekris; Chang-En Yu; Thomas D Bird; Debby W Tsuang
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-12       Impact factor: 2.680

5.  Introduction of hereditary disease-associated mutations into the beta-amyloid precursor protein gene of mouse embryonic stem cells: a comparison of homologous recombination methods.

Authors:  M Gschwind; G Huber
Journal:  Mol Cell Biol       Date:  1998-08       Impact factor: 4.272

6.  Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC.

Authors:  P H Jensen; P Hojrup; H Hager; M S Nielsen; L Jacobsen; O F Olesen; J Gliemann; R Jakes
Journal:  Biochem J       Date:  1997-04-15       Impact factor: 3.857

7.  Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging.

Authors:  William J Jagust; Susan M Landau
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

8.  Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues.

Authors:  M K Lee; H H Slunt; L J Martin; G Thinakaran; G Kim; S E Gandy; M Seeger; E Koo; D L Price; S S Sisodia
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

9.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

10.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.